Key Points
- CFO John Kirby purchased 3,536 shares at an average price of $4.24 on Nov. 25, raising his holding to 8,962 shares (a 65.17% increase), a transaction disclosed in an SEC Form 4 filing.
- Verrica beat quarterly expectations, reporting $0.13 EPS versus a consensus of -$1.14 and $14.34M in revenue versus $8.34M expected, but analysts still forecast -1.46 EPS for the fiscal year and the average street rating is "Reduce."
- Market snapshot: VRCA opened at $5.12 with a 12‑month range of $3.28–$13.60, a market cap of about $48.6M, a negative PE (-1.50), and 50/200‑day moving averages of $4.08/$5.44.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) CFO John Kirby bought 3,536 shares of the stock in a transaction dated Tuesday, November 25th. The shares were bought at an average cost of $4.24 per share, with a total value of $14,992.64. Following the completion of the purchase, the chief financial officer directly owned 8,962 shares of the company's stock, valued at approximately $37,998.88. This trade represents a 65.17% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Verrica Pharmaceuticals Price Performance
VRCA stock opened at $5.12 on Wednesday. Verrica Pharmaceuticals Inc. has a 12 month low of $3.28 and a 12 month high of $13.60. The firm's 50-day moving average is $4.08 and its 200 day moving average is $5.44. The company has a market capitalization of $48.59 million, a PE ratio of -1.50 and a beta of 1.70.
Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last issued its earnings results on Friday, November 14th. The company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of ($1.14) by $1.27. The company had revenue of $14.34 million during the quarter, compared to the consensus estimate of $8.34 million. Sell-side analysts forecast that Verrica Pharmaceuticals Inc. will post -1.46 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Verrica Pharmaceuticals in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Verrica Pharmaceuticals has an average rating of "Reduce".
View Our Latest Analysis on VRCA
Institutional Investors Weigh In On Verrica Pharmaceuticals
Several hedge funds have recently modified their holdings of the business. AQR Capital Management LLC boosted its stake in shares of Verrica Pharmaceuticals by 306.7% during the first quarter. AQR Capital Management LLC now owns 58,711 shares of the company's stock valued at $26,000 after purchasing an additional 44,275 shares in the last quarter. Qube Research & Technologies Ltd purchased a new stake in Verrica Pharmaceuticals during the second quarter worth $28,000. Invesco Ltd. boosted its position in Verrica Pharmaceuticals by 64.8% during the 1st quarter. Invesco Ltd. now owns 74,388 shares of the company's stock valued at $33,000 after acquiring an additional 29,256 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Verrica Pharmaceuticals by 127.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 99,505 shares of the company's stock valued at $44,000 after acquiring an additional 55,852 shares in the last quarter. Finally, Kovitz Investment Group Partners LLC purchased a new position in shares of Verrica Pharmaceuticals in the 1st quarter valued at $45,000. Hedge funds and other institutional investors own 42.45% of the company's stock.
Verrica Pharmaceuticals Company Profile
(
Get Free Report)
Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
